FT Global Pharmaceutical and Biotechnology Conference

The global life sciences industry is facing a level of disruption unprecedented in its long history. Once considered the holy grail of medicine, a new generation of gene-based therapies is dawning at last, holding out the promise of a paradigm shift from treatment to cure, but also challenging our healthcare systems’ ability to afford the new age of biology. China, meanwhile, is rising as a force to be reckoned with, both in terms of its potential for drug development, as well as in its ready embrace of digital technologies to transform R&D, disease management and services.